TY - JOUR
TI - Executive summary of the joint position paper on renal denervation of the Cardiovascular and Interventional Radiological Society of Europe and the European Society of Hypertension
AU - Moss, J.G.
AU - Belli, A.-M.
AU - Coca, A.
AU - Lee, M.
AU - Mancia, G.
AU - Peregrin, J.H.
AU - Redon, J.
AU - Reekers, J.A.
AU - Tsioufis, C.
AU - Vorwerk, D.
AU - Schmieder, R.E.
JO - JOURNAL OF HYPERTENSION
PY - 2016
VL - 34
TODO - 12
SP - 2303-2304
PB - Lippincott Williams and Wilkins
SN - -
TODO - 10.1097/HJH.0000000000001147
TODO - Article;  blood pressure;  evidence based medicine;  human;  hypertension;  kidney denervation;  medical literature;  medical society;  office blood pressure;  priority journal;  consensus;  Coronary Vasospasm;  denervation;  hypertension;  innervation;  kidney;  pathophysiology;  practice guideline, Blood Pressure;  Consensus;  Coronary Vasospasm;  Denervation;  Humans;  Hypertension;  Kidney;  Practice Guidelines as Topic
TODO - Renal denervation (RDN) was reported as a novel exciting treatment for resistant hypertension in 2009. An initial randomized trial supported its efficacy and the technique gained rapid acceptance across the globe. However, a subsequent large blinded, sham arm randomized trial conducted in the USA (to gain Food and Drug Administration approval) failed to achieve its primary efficacy end point in reducing office blood pressure at 6 months. Published in 2014 this trial received both widespread praise and criticism. RDN has effectively stopped out with clinical trials pending further evidence. This joint consensus document representing the European Society of Hypertension and the Cardiovascular and Radiological Society of Europe attempts to distill the current evidence and provide future direction and guidance. Copyright © 2016 Wolters Kluwer Health, Inc.
ER -